Search Results 71-80 of 16725 for GLP-1 agonists

  1. Type 2 diabetes - Symptoms and causes - Mayo Clinic

    Both type 1 and type 2 diabetes can begin during childhood and adulthood. Type 2 is more common in older adults. But the increase in the number of children ...

  2. Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes (REVITALIZE 1) - Mayo Clinic

    * GLP-1 RA including dual peptide agonists and related molecules (e.g., GLP-1/GIP RA), * DPP-4i, * TZDs, * SGLT2is, * SUs, * Meglitinides, * Insulin (basal ...

  3. A Study of the Effect of Liraglutide on Weight Loss and Stomach Functions in Obesity - Mayo Clinic

    Liraglutide, a long-acting GLP-1 receptor agonist, is approved for treatment of obesity; however, the mechanisms of action of liraglutide are incompletely ...

  4. Regenerative medicine and diabetes treatment - Mayo Clinic News Network

    The first, glucagon-like peptide 1 (GLP-1), a gastrointestinal hormone, stimulates the pancreas to make more beta cells, which increases the amount of insulin ...

  5. Publications - Layne M. Bettini, M.D., J.D. - Mayo Clinic

    Assessment of Gastric Content Using Gastric Ultrasound in Patients on Glucagon-Like Peptide-1 Receptor Agonists Before Anesthesia. Anesth Analg. 2026 Apr 1; 142 ...

  6. The International Diabetes Closed Loop Trial DCLP4 - Mayo Clinic

    Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1 year. ... GLP-1 agonists, DPP ...

  7. Dr. Andres Acosta Archives - Mayo Clinic News Network

    , another GLP-1 medication (sold under the brand names Ozempic and Wegovy), and results are expected soon. They are working to expand the test by ...

  8. Publications - Todd A. Kellogg, M.D. - Mayo Clinic

    Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity? Curr Atheroscler Rep. 2025 Nov 8; 27 (1):112 Epub 2025 Nov ...

  9. Type 2 Diabetes Clinical Trials - Mayo Clinic Research

    The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric ...

  10. Study Evaluating The Safety And Efficacy Of Semaglutide, And The Fixed-Dose Combination Of Cilofexor And Firsocostat, Alone And In Combination, In Participants With Compensated Cirrhosis (F4) Due To Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

    ... 1 trial. Phase 4 trials look at long ... - History of type 1 diabetes. - Treatment with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in the period